Biomarkers of alcohol consumption and related liver disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 70, Issue 5, 2010, Pages 305-312

  Niemelä, Onni ^a   Alatalo, Päivikki ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Aminotransferase; CDT; Ethanol; Fibrosis; GGT; NASH; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE DEFICIENT TRANSFERRIN; ETHYL GLUCURONIDE; GAMMA GLUTAMYLTRANSFERASE; PHOSPHATIDYLETHANOLAMINE;

ALCOHOL ABUSE; ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; CLINICAL ASSESSMENT; ERYTHROCYTE; FIBROGENESIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MEAN CORPUSCULAR VOLUME; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

ALANINE TRANSAMINASE; ALCOHOL DRINKING; ALCOHOLISM; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BODY MASS INDEX; ERYTHROCYTES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; OBESITY; TRANSFERRIN;

EID: 77956021602     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.486442     Document Type: Review

References (72)

1. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006;367:52-56
2. Lieber CS. Medical disorders of alcoholism. N Engl J Med 1995;333:1058-1065
3. Room R, Babor T, Rehm J. Alcohol and public health. Lancet 2005;365:519-530
4. Corrao G, Bagnardi V, Zambon A, La VC. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004;38:613-619
5. Gunzerath L, Faden V, Zakhari S, Warren K. National Institute on Alcohol Abuse and Alcoholism report on moderate drinking. Alcohol Clin Exp Res 2004;28:829-847
6. Alatalo PI, Koivisto HM, Hietala JP, Puukka KS, Bloigu R, Niemelä OJ. Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index. Am J Clin Nutr 2008;88:1097-1103
7. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:370-379
8. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49: 306-317
9. Wu D, Cederbaum AI. Oxidative stress and alcoholic liver disease. Semin Liver Dis 2009;29:141-154
10. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifi able and nonmodifi able factors. Gastroenterology 2008;134:1699-1714
11. Niemelä O. Biomarkers in alcoholism. Clin Chim Acta 2007;377:39-49.
12. Allen JP, Litten RZ. Recommendations on use of biomarkers in alcoholism treatment trials. Alcohol Clin Exp Res 2003; 27:1667-1670
13. Conigrave KM, Degenhardt LJ, Whitfield JB, Saunders JB, Helander A, Tabakoff B. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002;26:332-339
14. Das SK, Dhanya L, Vasudevan DM. Biomarkers of alcoholism: an updated review. Scand J Clin Lab Invest 2008;68: 81-92.
15. Niemelä O. Serum diagnosis of alcoholic liver disease and markers of ethanol intake. In: Sherman DIN, Preedy V, Watson RR, editors. Ethanol and the liver. New York and London: Taylor and Francis; 2002. pp. 411-449
16. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245:194-205.
17. Rockey DC, Bissell DM. Noninvasive measures of liver fi brosis. Hepatology 2006;43:S113-20.
18. Rosman AS, Lieber CS. Diagnostic utility of laboratory tests in alcoholic liver disease. Clin Chem 1994;40:1641-1651
19. Savola O, Niemelä O, Hillbom M. Blood alcohol is the best indicator of hazardous alcohol drinking in young adults and working-age patients with trauma. Alcohol Alcohol 2004;39: 340-345
20. Helander A, Bö t tcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxifi cation. Alcohol Alcohol 2009;44:55-61.
21. Bö t tcher M, Beck O, Helander A. Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol Alcohol 2008;43:46-48
22. Helander A, Olsson I, Dahl H. Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identifi cation of alcohol consumption. Clin Chem 2007;53:1855-1857
23. Helander A, Zheng Y. Molecular species of the alcohol biomarker phosphatidylethanol in human blood measured by LC-MS. Clin Chem 2009;55:1395-1405
24. Nissinen AE, Mäk elä SM, Vuoristo JT, Liisanantti MK, Hannuksela ML, H ö rkk ö S, Savolainen MJ. Immunological detection of in vitro formed phosphatidylethanol-an alcohol biomarker-with monoclonal antibodies. Alcohol Clin Exp Res 2008;32:921-928
25. Freeman TL, Tuma DJ, Thiele GM, Klassen LW, Worrall S, Niemela O, Parkkila S, Emery PW, Preedy VR. Recent advances in alcohol-induced adduct formation. Alcohol Clin Exp Res 2005;29:1310-1316
26. Niemelä O, Parkkila S, Ylä-Herttuala S, Villanueva J, Ruebner B, Halsted CH. Sequential acetaldehyde production, lipid peroxidation, and fi brogenesis in micropig model of alcohol-induced liver disease. Hepatology 1995;22: 1208-1214
27. Latvala J, Hietala J, Koivisto H, Jä r vi K, Anttila P, Niemelä O. Immune responses to ethanol metabolites and cytokine profi les differentiate alcoholics with or without liver disease. Am J Gastroenterol 2005;100:1303-1310
28. Jeppsson JO, Arndt T, Schellenberg F, Wielders JP, Anton RF, Whitfield JB, Helander A. Toward standardization of carbohydrate-defi cient transferrin (CDT) measurements: I. Analyte defi nition and proposal of a candidate reference method. Clin Chem Lab Med 2007;45:558-562
29. Anton RF, Lieber C, Tabakoff B. Carbohydrate-defi cient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study. Alcohol Clin Exp Res 2002;26:1215-1222
30. Burke V, Puddey IB, Rakic V, Swanson NR, Dimmitt SB, Beilin LJ, Ching S, Beilby JP. Carbohydrate-defi cient transferrin as a marker of change in alcohol intake in men drinking 20 to 60 g of alcohol per day. Alcohol Clin Exp Res 1998; 22:1973-1980
31. Mikkelsen IM, Kanitz RD, Nilssen O, Huseby NE. Carbohydrate-defi cient transferrin: marker of actual alcohol consumption or chronic alcohol misuse? Alcohol Alcohol 1998; 33:646-650
32. Schmidt LG, Schmidt K, Dufeu P, Ohse A, Rommelspacher H, Muller C. Superiority of carbohydrate-defi cient transferrin to gamma-glutamyltransferase in detecting relapse in alcoholism. Am J Psychiatry 1997;154:75-80.
33. Hietala J, Koivisto H, Anttila P, Niemelä O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2006;41:528-533
34. Lee DH, Ha MH, Kam S, Chun B, Lee J, Song K, Boo Y, Steffen L, Jacobs DR, Jr. A strong secular trend in serum gamma-glutamyltransferase from 1996 to 2003 among South Korean men. Am J Epidemiol 2006;163:57-65.
35. Puukka K, Hietala J, Koivisto H, Anttila P, Bloigu R, Niemelä O. Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase activity. Am J Clin Nutr 2006;83:1351-1354
36. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and longterm survival: is it just the liver? Clin Chem 2007;53:940-946
37. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363-1370
38. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009;136: 477-485
39. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-2137
40. Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ, III. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008;47:880-887
41. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967
42. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005;3:1260-1268
43. Ioannou GN. Implications of elevated serum alanine aminotransferase levels: think outside the liver. Gastroenterology 2008;135:1851-1854
44. St George A., Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50: 68-76.
45. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Sr., Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008;135:1935-44, 1944.
46. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 2006;26:1209-1216
47. Alatalo P, Koivisto H, Puukka K, Hietala J, Anttila P, Bloigu R, Niemelä O. Biomarkers of liver status in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2009;44: 199-203.
48. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. The effect of alcohol consumption on the prevalence of iron overload, iron defi ciency, and iron defi ciency anemia. Gastroenterology 2004;126:1293-1301
49. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990;11:127-137
50. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002;122: 281-289
51. Tsukamoto H, Horne W, Kamimura S, Niemelä O, Parkkila S, Ylä -Herttuala S, Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 1995;96:620-630
52. Lee DH, Jacobs DR, Jr. Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. Med Hypotheses 2004;62:442-445
53. Tyulina OV, Prokopieva VD, Boldyrev AA, Johnson P. Erythrocyte and plasma protein modifi cation in alcoholism: a possible role of acetaldehyde. Biochim Biophys Acta 2006;1762: 558-563
54. Arroyo V. Human serum albumin: not just a plasma volume expander. Hepatology 2009;50:355-357
55. Johnson RJ, Rivard C, Nakagawa T, Sautin YY, Sanchez-Lozada LG. Uric acid: more to learn, more experiments to do. Am J Hypertens 2009;22:952-953
56. Alatalo PI, Koivisto HM, Hietala JP, Bloigu RS, Niemelä OJ. Gender-dependent impacts of body mass index and moderate alcohol consumption on serum uric acid-an index of oxidant stress status? Free Radic Biol Med 2009;46:1233-1238
57. Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, Escalera S, Dziura J, Taksali SE, Kursawe R, Shaw M, Savoye M, Pierpont B, Constable RT, Caprio S. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 2009;49:1896-1903
58. Latvala J, Parkkila S, Niemelä O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol Clin Exp Res 2004;28:619-624
59. Koivisto H, Hietala J, Anttila P, Parkkila S, Niemelä O. Longterm ethanol consumption and macrocytosis: diagnostic and pathogenic implications. J Lab Clin Med 2006;147:191-196
60. Lindenbaum J. Hematologic complications of alcohol abuse. Semin Liver Dis 1987;7:169-181
61. Bataller R, Brenner DA. Liver fi brosis. J Clin Invest 2005; 115:209-218
62. Niemelä O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H. Markers of fi brogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990;98:1612-1619
63. Iredale JP. Models of liver fi brosis: exploring the dynamic nature of infl ammation and repair in a solid organ. J Clin Invest 2007;117:539-548
64. Koivisto H, Hietala J, Niemelä O. An inverse relationship between markers of fi brogenesis and collagen degradation in patients with or without alcoholic liver disease. Am J Gastroenterol 2007;102:773-779
65. Vidali M, Hietala J, Occhino G, Ivaldi A, Sutti S, Niemela O, Albano E. Immune responses against oxidative stress-derived antigens are associated with increased circulating tumor necrosis factor-alpha in heavy drinkers. Free Radic Biol Med 2008;45:306-311
66. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prevot S, Ngo Y, Munteanu M, Balian A, Njike-Nakseu M, Perlemuter G, Poynard T. Diagnostic and prognostic values of noninvasive biomarkers of fi brosis in patients with alcoholic liver disease. Hepatology 2009;49:97-105.
67. Schenker S. Medical consequences of alcohol abuse: is g ender a factor? Alcohol Clin Exp Res 1997;21:179-181
68. Breitling LP, Raum E, Muller H, Rothenbacher D, Brenner H. Synergism between smoking and alcohol consumption with respect to serum gamma-glutamyltransferase. Hepatology 2009; 49:802-808
69. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006; 166:1190-1195
70. Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 2009;50:175-184
71. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, George J. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-1112
72. Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehntopf M, Stumvoll M, Kahn CR, Bluher M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009;106:8665-8670